Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex stops VX-745 trials

Executive Summary

Vertex will not proceed with enrollment in the higher-dose cohort in Phase II trials with orally active p38 MAP kinase inhibitor VX-745 following the finding of adverse effects within the central nervous system in one of two animal species receiving high-dose exposure. The company will move ahead on second-generation p38 inhibitors VX-702 and VX-850 for treatment of inflammatory disease, initiating clinical studies with one or both of the candidates in the first half of 2002
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS038610

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel